Director’s Strategic Move: Vicarious Surgical Stock Sale Unveiled

New insider activity at Vicarious Surgical ( (RBOT) ) has taken place on August 21, 2025.

Director Donald F Tang recently sold 2,159 shares of Vicarious Surgical stock, amounting to a total value of $13,104.

Recent Updates on RBOT stock

In the past 24 hours, Vicarious Surgical Inc. has experienced notable developments following its Q2 earnings call. The company reported a reduction in operating expenses and net loss, indicating improved financial management. However, challenges such as delays in clinical trials and system readiness issues have emerged, impacting the company’s development timeline. The appointment of Stephen From as the new CEO is seen as a positive step towards future growth, although immediate uncertainties remain. Piper Sandler adjusted its price target for Vicarious Surgical, citing the company’s shift in focus from achieving first clinical use by year-end to completing a fully integrated, production-equivalent system. This strategic pivot reflects the company’s prioritization of system readiness and design lock, influencing the revised outlook.

Spark’s Take on RBOT Stock

According to Spark, TipRanks’ AI Analyst, RBOT is a Underperform.

Vicarious Surgical’s stock score reflects significant financial challenges as a pre-revenue company with high cash burn, offset by a moderately stable balance sheet. Technical analysis indicates bearish sentiment, compounded by valuation challenges due to negative earnings. While the earnings call showed strategic advancements, supply chain delays and NYSE compliance issues pose risks. Successful clinical trials and improved cash management will be critical for future performance.

To see Spark’s full report on RBOT stock, click here.

More about Vicarious Surgical

YTD Price Performance: -57.37%

Average Trading Volume: 24,947

Technical Sentiment Signal: Strong Sell

Current Market Cap: $38.15M